Malin Fagerås
- Differential dropout may affect exacerbation risk estimates differently in moderate-to-very severe COPDBy Peter Calverley, Göran Eriksson, Dirkje Postma, Christine Jenkins, Antonio Anzueto, Barry Make, Anders Persson, Malin Fagerås and Thomas SimilowskiPeter Calverley1Pulmonary and Rehabilitation Research Group, University Hospital Aintree, Liverpool, United KingdomGöran Eriksson2Research and Development, AstraZeneca, Lund, Sweden3Department of Respiratory Medicine and Allergology, University Hospital, Lund, SwedenDirkje Postma4Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, GRIAC Research Institute, University of Groningen, NetherlandsChristine Jenkins5Woolcock Institute of Medical Research, University of Sydney, Camperdown, AustraliaAntonio Anzueto6Department of Pulmonology, University of Texas Health Sciences Center, San Antonio, TX, United StatesBarry Make7Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, University of Colorado, Denver, CO, United StatesAnders Persson8Research and Development, AstraZeneca, Mölndal, SwedenMalin Fagerås2Research and Development, AstraZeneca, Lund, SwedenThomas Similowski9Service de Pneumologie et Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
- Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and DBy Antonio Anzueto, Christine R. Jenkins, Barry J. Make, Magnus Lindberg, Peter M. Calverley, Malin Fagerås, Dirkje S. Postma, Stephen I. Rennard and Donald P. TashkinArticle | Published in 2015 in European Respiratory JournalAntonio Anzueto1Department of Pulmonary/Critical Care, University of Texas Health Sciences Centre, and South Texas Veterans Healthcare System, San Antonio, TX, USAChristine R. Jenkins2The George Institute for Global Health, Sydney, AustraliaBarry J. Make3Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, University of Colorado, Denver, CO, USAMagnus Lindberg4AstraZeneca R&D, Mölndal, SwedenPeter M. Calverley5Pulmonary and Rehabilitation Research Group, University Hospital Aintree, Liverpool, UKMalin Fagerås4AstraZeneca R&D, Mölndal, SwedenDirkje S. Postma6University of Groningen, University Medical Center Groningen, GRIAC Research Institute, The NetherlandsStephen I. Rennard7Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, NE, USADonald P. Tashkin8David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and DBy Antonio Anzueto, Christine R. Jenkins, Barry J. Make, Magnus Lindberg, Peter M. Calverley, Malin Fagerås, Dirkje S. Postma, Stephen I. Rennard and Donald P. TashkinAntonio Anzueto1Department of Pulmonary/Critical Care, University of Texas Health Sciences Centre, and South Texas Veterans Healthcare System, San Antonio, TX, USAChristine R. Jenkins2The George Institute for Global Health, Sydney, AustraliaBarry J. Make3Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, University of Colorado, Denver, CO, USAMagnus Lindberg4AstraZeneca R&D, Mölndal, SwedenPeter M. Calverley5Pulmonary and Rehabilitation Research Group, University Hospital Aintree, Liverpool, UKMalin Fagerås4AstraZeneca R&D, Mölndal, SwedenDirkje S. Postma6University of Groningen, University Medical Center Groningen, GRIAC Research Institute, The NetherlandsStephen I. Rennard7Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, NE, USADonald P. Tashkin8David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- CompEx – A novel composite asthma exacerbation endpointBy Anne Fuhlbrigge, Thomas Bengtsson, Stefan Peterson, Alexandra Jauhiainen and Malin FagerasAnne Fuhlbrigge1Brigham and Women's Hospital, Harvard Medical School, Boston, United StatesThomas Bengtsson2StatMind, StatMind AB, Lund, SwedenStefan Peterson2StatMind, StatMind AB, Lund, SwedenAlexandra Jauhiainen3Early Clinical Biometrics, AstraZeneca R&D, Molndal, SwedenMalin Fageras4Global Medical Affairs, AstraZeneca R&D, Molndal, Sweden
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.